DOI: 10.5061/dryad.ttdz08m9t
title: Multi-racial cytokine profiling reveals immune dysregulation, not chronic inflammation, in polycystic ovary syndrome

description: This dataset contains plasma concentrations of 96 immune-related proteins
 measured using a custom Luminex xMAP assay in 40 women (20 with PCOS, 20
 controls) matched for age, BMI, and race (Black and White). The
 comprehensive panel includes: Growth Factors (12): EGF, FGF-2, FLT3L,
 G-CSF, GM-CSF, M-CSF, PDGF-AA, PDGF-AB, SCF, TGF-α, TPO, and VEGF-A
 Cytokines (35): APRIL, BAFF, IFN-α2, IFN-β, IFN-γ, IFN-ω, IL-1α, IL-1β,
 IL-1Rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12p40,
 IL12-p70, IL-13, IL-15, IL-16, IL-17A, IL-17E, IL-17F, IL-18, IL-20,
 IL-21, IL-22, IL-23, IL-24, IL-27, IL-28A, IL-29, IL-31, IL-33, IL-34,
 IL-35, LIF, TNF-α, TNF-β, and TSLP Chemokines (41): Including 6CKINE,
 BCA1, CCL28, CTACK, CXCL16, ENA78, EOTAXIN variants, FRACTALKINE, GCP2,
 GRO-α, IP-10, MCP variants, MIP variants, RANTES, and others Other
 Immune-Related Proteins (8): CD137, CD40L, Granzyme A, Granzyme B,
 Perforin, sFAS, sFASL, and TRAIL
description: <strong>Study Participants and Cohort Design</strong>
 Samples were obtained from a prospective study of over 2500 women and
 adolescents (aged ≥14 years) presenting for evaluation of androgen excess
 at reproductive endocrinology clinics. PCOS was defined using the 1990
 National Institutes of Health (NIH) criteria. For this analysis, we
 performed a cross-sectional case-control study with a subsampled cohort of
 40 women: 20 with PCOS and 20 controls, matched for race (10 White, 10
 Black in each group), age, and BMI. Fasting blood samples were obtained
 during the follicular phase (cycle days 3-8), and plasma was separated and
 cryopreserved. <strong>Luminex
 Assay</strong> Plasma samples (10 μL) were analyzed using blinded
 Xmap Intelliflex Luminex assays. CRP was measured at 1:40,000 dilution,
 while 96 cytokines were measured without dilution using comprehensive
 custom immune protein panels: Human Cytokine/Chemokine/Growth Factor panel
 A (Cat# HCYTA-60K-PXBK48) and panel B (Cat# HCYTB-60K-PXBK48), and Human
 Cardiovascular Disease panel for CRP (Cat# HCVD3MAG-67K) (Millipore).
 Standard curves were generated, and concentrations interpolated using
 Belysa Immunoassay Curve Fitting software.
description: # Multi-racial cytokine profiling reveals immune dysregulation, not
 chronic inflammation, in polycystic ovary syndrome Dataset DOI:
 [10.5061/dryad.ttdz08m9t](10.5061/dryad.ttdz08m9t) ## Description of the
 data and file structure **Study Participants and Cohort Design** Samples
 were obtained from a prospective study of over 2500 women and adolescents
 (aged ≥14 years) presenting for evaluation of androgen excess at
 reproductive endocrinology clinics. PCOS was defined using the 1990
 National Institutes of Health (NIH) criteria. For this analysis, we
 performed a cross-sectional case-control study with a subsampled cohort of
 40 women: 20 with PCOS and 20 controls, matched for race (10 White, 10
 Black in each group), age, and BMI. Fasting blood samples were obtained
 during the follicular phase (cycle days 3-8), and plasma was separated and
 cryopreserved. **Luminex Assay** Plasma samples (10 μL) were analyzed
 using blinded Xmap Intelliflex Luminex assays. CRP was measured at
 1:40,000 dilution, while 96 cytokines were measured without dilution using
 comprehensive custom immune protein panels: Human
 Cytokine/Chemokine/Growth Factor panel A (Cat# HCYTA-60K-PXBK48) and panel
 B (Cat# HCYTB-60K-PXBK48), and Human Cardiovascular Disease panel for CRP
 (Cat# HCVD3MAG-67K) (Millipore). Standard curves were generated, and
 concentrations interpolated using Belysa Immunoassay Curve Fitting
 software. ### Files and variables #### File: Supplemental_File_1.xlsx
 **Description:** Concentrations of 96 cytokines. All variable
 abbreviations and units are indicated in the key tab. Missing or
 undetectable values are indicated by "-". ##### Variables *
 Control/PCOS * Age * Black/White * BMI * SCD40L * EGF * EOTAXIN * FGF2 *
 FLT3L * FRACTALKINE * GCSF * GMCSF * GROA * IFNA2 * IFNY * IL1A * IL1B *
 IL1RA * IL2 * IL3 * IL4 * IL5 * IL6 * IL7 * IL8 * IL9 * IL10 * IL12P40 *
 IL12P70 * IL13 * IL15 * I17A * IL17E * IL17F * IL18 * IL22 * IL27 * IP10 *
 MCP1 * MCP3 * MCSF * MDC * MIGCXL9 * MIP1A * MIP1B * PDGFAA * PDGFAB *
 RANTES * TGFA * TNFA * TNFB * VEGFA * 6CKINE * BCA1 * SFAS * SFASL *
 SCD137 * APRIL * BAFF * IL16 * CCL28 * CTACK * CXCL16 * ENA17A * GRANZYMEA
 * EOTAXIN2 * EOTAXIN3 * IL35 * GCP2 * HNGB1 * I309 * GRANZYMEB * IFNB *
 IFNW * IL11 * IL23 * IL20 * IL24 * IL28A * IL31 * IL29 * IL33 * IL21 *
 IL34 * LIF * LIMPHOTACTIN * MCP2 * MCP4 * MIP1Y * MIP3A * ITAC * MIP3B *
 MPIF1 * SCF * CDF1 * TARC * TPO * TRAIL * TSLP * PERFORIN ## Software This
 is an .xlsx file. Read with Microsoft Excel. ## Access information N/A ##
 Human subjects data This dataset contains completely de-identified human
 subjects data that complies with Dryad's standards for public domain
 publication. The original study was conducted under institutional review
 board approval at the University of Alabama at Birmingham and Cedars-Sinai
 Medical Center between 1987 and 2010. Written informed consent was
 obtained from all participants, including explicit consent for future
 research use of biological samples and associated de-identified data. The
 dataset has been thoroughly de-identified and contains only the following
 variables: cytokine concentrations (96 analytes), self-reported race
 (White/Black), PCOS diagnosis status, BMI, and age. All direct identifiers
 have been removed, including participant codes, dates, geographic
 identifiers, and any other information that could potentially identify
 individual participants. No linking codes or keys exist that could
 re-identify participants. The de-identification process ensures compliance
 with applicable privacy regulations and ethical guidelines for human
 subjects research. The data represents aggregate measurements suitable for
 scientific analysis while protecting participant privacy. All participants
 provided informed consent for the use of their biological samples and
 associated clinical data for research purposes, including publication of
 de-identified results.